AstraZeneca third-quarter revenue rises 7% as oncology growth offsets Farxiga decline
AstraZeneca reported Q3 2026 revenue of $16.21B, up 7% at CER. Core EPS rose 19% to $2.79, while reported EPS climbed 26% to $2.02. Core operating profit grew 20% to $5.86B. Nine-month revenue reached $46.88B, up 7%, with core EPS of $8, up 14%.
How this was made
The 30-second read
Why it matters
The earnings beat is likely to lift the stock in the short term, while sector peers may see spill‑over gains.
Market read
A major earnings release with material revenue and EPS beat, relevant for traders targeting pharma stocks.
What to watch
Potential regulatory scrutiny on oncology pipeline and currency headwinds could temper upside
Background
AstraZeneca's Q3 2026 earnings release provides the latest performance snapshot for the pharma giant.
Ticker impact
AstraZeneca reported Q3 2026 revenue of $16.21 bn, up 7% at constant exchange rates, and core EPS rose 19% to $2.79.
likely upward as the market prices in the revenue and earnings beat
Revenue and EPS both exceeded expectations, indicating stronger operating performance.
Market effects
supports broader pharma sector momentum
beneficial for UK and European markets where AstraZeneca has a large presence
moderate, as the drugmaker is a major global player
Counterpoint
Growth in oncology may not sustain long‑term momentum, and Farxiga decline could signal broader diabetes market weakness
Key entities
- CompanyAstraZeneca
Global pharmaceutical company reporting Q3 2026 results
